S-8 1 s-82020.htm S-8 Document
As filed with the U.S. Securities and Exchange Commission on March 15, 2021
Registration No. 333-

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
__________________________
PHASEBIO PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
__________________________
Delaware
03-0375697
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
1 Great Valley Parkway, Suite 30
Malvern, Pennsylvania 19355
(610) 981-6500
(Address of principal executive offices, including zip code)

PhaseBio Pharmaceuticals, Inc. 2018 Equity Incentive Plan
PhaseBio Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan
(Full titles of the plans)
__________________________
Jonathan P. Mow
Chief Executive Officer
PhaseBio Pharmaceuticals, Inc.
1 Great Valley Parkway, Suite 30
Malvern, Pennsylvania 19355
(610) 981-6500
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
Copies to:
Christian E. Plaza
Darren K. DeStefano
Madison A. Jones
Cooley LLP
11951 Freedom Drive
Reston, Virginia 20190
(703) 456-8000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
¨
Accelerated filer
¨
Non-accelerated filer
x
Emerging growth company
x
Smaller reporting company
x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
1




CALCULATION OF REGISTRATION FEE
Title of Securities to be Registered
Amount to be Registered(1)
Proposed Maximum Offering Price per Share
Proposed Maximum Aggregate Offering Price
Amount of Registration Fee
Common Stock, par value $0.001 per share
– 2018 Equity Incentive Plan
883,257 (2)
$4.27 (4)
$3,771,507$411.47
– 2018 Employee Stock Purchase Plan
294,419 (3)
$3.63 (5)
$1,068,741$116.60
Total
1,177,676$4,840,248$528.07
(1)Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of Registrant’s common stock that become issuable under the plans set forth herein by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant’s common stock.
(2)Represents an automatic annual increase equal to 3% of the total number of shares of the Registrant’s capital stock outstanding on December 31st of the preceding calendar year to the aggregate number of shares of the Registrant’s common stock reserved for issuance under, and which annual increase is provided by, the Registrant’s 2018 Equity Incentive Plan (as amended, the “2018 Plan”).
(3)Represents an automatic increase equal to 1% of the total number of shares of the Registrant’s capital stock outstanding on December 31st of the preceding calendar year to the aggregate number of shares of the Registrant’s common stock reserved for issuance under, and which annual increase is provided by, the Registrant’s 2018 Employee Stock Purchase Plan (the “2018 ESPP”).
(4)Estimated in accordance with Rule 457(c) and (h) solely for purposes of calculating the registration fee on the basis of $4.27, the average of the high and low prices of the Registrant’s common stock as reported on the Nasdaq Global Market on March 11, 2021.
(5)Estimated in accordance with Rule 457(c) and (h) solely for the purpose of calculating the registration fee on the basis of $3.63, the average of the high and low prices of the Registrant’s common stock as reported on the Nasdaq Global Market on March 11, 2021, multiplied by 85%, which is the percentage of the price per share applicable to purchases under the 2018 ESPP.
2


REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E
Pursuant to General Instruction E of Form S-8, PhaseBio Pharmaceuticals, Inc. (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register (1) 883,257 additional shares of its common stock under the 2018 Plan, pursuant to the provisions of the 2018 Plan providing for an automatic increase in the number of shares of common stock reserved and available for issuance under the 2018 Plan on January 1, 2021 and (2) 294,419 additional shares of its common stock under the 2018 ESPP, pursuant to the provisions of the 2018 ESPP providing for an automatic increase in the number of shares of common stock reserved and available for issuance under the 2018 ESPP on January 1, 2021. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.
The contents of the Registrant’s Registration Statement on Form S-8 (File No. 333-237462), filed with the Commission on March 30, 2020, are incorporated by reference into this Registration Statement.
PART II
Item 3        Incorporation of Certain Documents by Reference
The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:
(a)The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the Commission on March 15, 2021;
(b)All other reports of the Registrant filed pursuant to Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (1) above (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items);
(c)The description of the Registrant’s common stock, which is contained in a registration statement on Form 8-A filed on October 9, 2018 (File No. 001-38697) under the Exchange Act, including any amendment or report filed for the purpose of updating such description; and
(d)All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
3


Item 8        Exhibits
___________
*    Filed herewith
4



SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Malvern, Pennsylvania, on March 15, 2021.
PHASEBIO PHARMACEUTICALS, INC.
By:
/s/ Jonathan P. Mow
Jonathan P. Mow
President and Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jonathan P. Mow and John P. Sharp, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to sign any registration statement for the same offering covered by this Registration Statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
5


Signature
Title
Date
/s/ Jonathan P. Mow
President, Chief Executive Officer and Director
March 15, 2021
Jonathan P. Mow
(Principal Executive Officer)
/s/ John P. Sharp
Chief Financial Officer
March 15, 2021
John P. Sharp
(Principal Financial Officer and Principal Accounting Officer)
/s/ Clay B. Thorp
Chairman of the Board of Directors
March 15, 2021
Clay B. Thorp
/s/ Edmund P. Harrigan
Director
March 15, 2021
Edmund P. Harrigan, M.D.
/s/ Nancy J. Hutson
Director
March 15, 2021
Nancy J. Hutson, Ph.D.
/s/ Peter Justin Klein
Director
March 15, 2021
Peter Justin Klein, M.D., J.D.
/s/ Caroline M. Loewy
Director
March 15, 2021
Caroline M. Loewy
/s/ Alex C. Sapir
Director
March 15, 2021
Alex C. Sapir
/s/ Richard A. van den Broek
Director
March 15, 2021
Richard A. van den Broek

6